1. |
潘敏翔, 吴久鸿, 郭丽. 抗癫药的药物经济学研究[J]. 药品评价, 2011, 8(20):30-34.
|
2. |
The Lancet Neurology. EURAP Signals a new era in epilepsy research[J]. Lancet Neurol, 2011, 10(7):591.
|
3. |
Thomas SV, Syam U, Devi JS. Predictors of seizures during pregnancy in women with epilepsy[J]. J Sucharitha Devi Epilepsia, 2012, 53(5):85-88.
|
4. |
Kulaga S, Sheehy O, Zargarzadeh AH,et al. Antiepileptic drug use during pregnancy:perinatal outcomes[J]. Seizure, 2011, 20(9):667-672.
|
5. |
Borthen I, Eide M, Daltveit A, et al. Obstetric outcome in women with epilepsy:a hospital-based, retrospective study[J]. BJOG, 2011, 118(8):956-965.
|
6. |
Naseer MI, Shupeng L, Kim MO. Maternal epileptic seizure induced by pentylenetetrazol:apoptotic neurodegeneration and decreased GABAB1 receptor expression in prenatal rat brain[J]. Mol Brain, 2009(2):20.
|
7. |
Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives[J]. Neurology, 2006, 67(12, Suppl 4):56-58.
|
8. |
Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs[J]. Expert Rev Neurother, 2010, 10(1):119-140.
|
9. |
Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women[J]. Epilepsia, 2002, 43(7):697-702.
|
10. |
Sabers A, Christensen J. No effect of oral contraceptives on the metabolism of levetiracetam[J]. Epilepsy Res, 2011, 95(3):277-279.
|
11. |
Vajda FJ, Hitchcock A, Graham J, et al. Seizure control in antiepileptic drug-treated pregnancy[J]. Epilepsia, 2008, 49(1):172-176.
|
12. |
Aberd EU, Obst D, Lond RWS, et al. Folic acid metabolism and human embryopathy[J]. Lancet, 1965, 285(7398):1254-1256.
|
13. |
Bauer J, Bös M, Rück J, et al. Evaluation of folate substitution in women with epilepsy. Determination of erythrocyte folic acid concentrations[J]. Der Nervenarzt, 2011, 82(4):459-461.
|
14. |
Pittschieler S, Brezinka C, Jahn B, et al. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy[J]. J Neur, 2008, 255(12):1926-1931.
|
15. |
Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy[J]. Neurology, 2012, 78(21):1692-1699.
|
16. |
Vajda FJ, Graham JE, Hitchcock AA, et al. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register[J]. Seizure, 2010, 19(9):558-561.
|
17. |
Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs:an analysis of data from the EURAP epilepsy and pregnancy registry[J]. Lancet Neurol, 2011, 10(7):609-617.
|
18. |
Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy[J]. Epilepsia, 2009, 50(9):2163-2166.
|
19. |
Sabers A. Algorithm for lamotrigine dose adjustment before, during and after pregnancy[J]. Acta Neurol Scand, 2012, 126(1):1-4.
|
20. |
Ozer FD, Demirel A, Yılmaz Dilsiz O, et al. Effects of Levetiracetam on neural tube development and closure of the chick embryos in ovo[J]. Childs Nerv Syst, 2012, 28(7):969-976.
|
21. |
Longo B, Forinash AB, Murphy JA. Levetiracetam use in pregnancy[J]. Ann Pharmacother, 2009, 43(10):1692-1695.
|
22. |
Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures[J]. Neuropsychiatr Dis Treat, 2009(5):467-476.
|
23. |
Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation[J]. Epilepsia, 2007, 48(6):1111-1116.
|
24. |
Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy[J]. Curr Med Res Opin, 2005, 21(5):693-701.
|
25. |
Uludag S, Aydin Y, Yilmaz O. Multiple fetal anomalies in association with topiramate and oxcarbezepine treatment[J]. Fetal Pediatr Pathol, 2012, 31(3):154-158.
|
26. |
Petrenaite V, Sabers A, Hansen-Schwartz J, et al. Seizure deterioration in women treated with oxcarbazepine during pregnancy[J]. Epilepsy Res, 2009, 84(2-3):245-249.
|
27. |
Ohman I, Sabers A, de Flon P, et al. Pharmacokinetics of topiramate during pregnancy[J]. Epilepsy Res, 2009, 87(2-3):124-129.
|
28. |
Westin AA, Nakken KO, Johannessen SI, et al. Serumconcentration/dose ratio of topiramate during pregnancy[J]. Epilepsia, 2009, 50(3):480-485.
|
29. |
Prakash, Prabhu LV,Rai R, et al. Teratogenic effects of the anticonvulsant gabapentin in mice[J]. Singapore Med J, 2008, 49(1):47-53.
|
30. |
Afshar M, Hassanzadeh-Taheri MM, Moallem SA, et al. Teratogenic effects of gabapentin on the skeletal system of Balb/C mice fetuses[J]. Neurosciences (Riyadh), 2009, 14(3):239-244.
|
31. |
Ozkan H, Cetinkaya M, Köksal N, et al. Severe fetal valproate syndrome:combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly[J]. J Matern Fetal Neonatal Med, 2011, 24(3):521-524.
|
32. |
Meador KJ, Baker GA, Browning N, et al. Effects of breastfeeding in children of women taking antiepileptic drugs[J]. Neurology, 2010, 75(22):1954-1960.
|
33. |
Chen L, Liu F, Yoshida S, et al. Is breast-feeding of infants advisable for epileptic mothers taking antiepileptic drugs?[J] Psychiatry Clin Neurosci, 2010, 64(5):460-468.
|
34. |
Sun Y, Vestergaard M, Christensen J, et al. Breastfeeding and risk of epilepsy in childhood:a birth cohort study[J]. J Pediatr, 2011, 158(6):924-929.
|
35. |
Kazmin A, Wong RC, Sermer M, et al. Antiepileptic drugs in pregnancy and hemorrhagic disease of the newborn an update[J]. Can Fam Physician, 2010,56(12):1291-1292.
|
36. |
Sabers A. Influences on seizure activity in pregnant women with epilepsy[J]. Epilepsy Behav, 2009, 15(2):230-234.
|